Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice

Jesús Gomeza(Eli Lilly (United States)), Harlan E. Shannon(Eli Lilly (United States)), Evi Kostenis(Eli Lilly (United States)), Christian C. Felder(Eli Lilly (United States)), Lu Zhang(Eli Lilly (United States)), Jesse Brodkin(Eli Lilly (United States)), Alexander Grinberg(Eli Lilly (United States)), Hui Z. Sheng(Eli Lilly (United States)), Jürgen Wess(Eli Lilly (United States))
Proceedings of the National Academy of Sciences
February 16, 1999
Cited by 350Open Access

Abstract

Members of the muscarinic acetylcholine receptor family (M1-M5) are known to be involved in a great number of important central and peripheral physiological and pathophysiological processes. Because of the overlapping expression patterns of the M1-M5 muscarinic receptor subtypes and the lack of ligands endowed with sufficient subtype selectivity, the precise physiological functions of the individual receptor subtypes remain to be elucidated. To explore the physiological roles of the M2 muscarinic receptor, we have generated mice lacking functional M2 receptors by using targeted mutagenesis in mouse embryonic stem cells. The resulting mutant mice were analyzed in several behavioral and pharmacologic tests. These studies showed that the M2 muscarinic receptor subtype, besides its well documented involvement in the regulation of heart rate, plays a key role in mediating muscarinic receptor-dependent movement and temperature control as well as antinociceptive responses, three of the most prominent central muscarinic effects. These results offer a rational basis for the development of novel muscarinic drugs.


Related Papers

No related papers found

Powered by citation graph analysis